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Abstract
Hepatic encephalopathy (HE) represents a dysfunctional gut-liver-brain axis in cirrhosis which can negatively impact
outcomes. This altered gut-brain relationship has been treated using gut-selective antibiotics such as rifaximin, that improve
cognitive function in HE, especially its subclinical form, minimal HE (MHE). However, the precise mechanism of the action of
rifaximin in MHE is unclear. We hypothesized that modulation of gut microbiota and their end-products by rifaximin would
affect the gut-brain axis and improve cognitive performance in cirrhosis. Aim To perform a systems biology analysis of the
microbiome, metabolome and cognitive change after rifaximin in MHE.
Methods: Twenty cirrhotics with MHE underwent cognitive testing, endotoxin analysis, urine/serum metabolomics (GC and
LC-MS) and fecal microbiome assessment (multi-tagged pyrosequencing) at baseline and 8 weeks post-rifaximin 550 mg
BID. Changes in cognition, endotoxin, serum/urine metabolites (and microbiome were analyzed using recommended
systems biology techniques. Specifically, correlation networks between microbiota and metabolome were analyzed before
and after rifaximin.
Results: There was a significant improvement in cognition(six of seven tests improved,p,0.01) and endotoxemia (0.55 to
0.48 Eu/ml, p = 0.02) after rifaximin. There was a significant increase in serum saturated (myristic, caprylic, palmitic,
palmitoleic, oleic and eicosanoic) and unsaturated (linoleic, linolenic, gamma-linolenic and arachnidonic) fatty acids post-
rifaximin. No significant microbial change apart from a modest decrease in Veillonellaceae and increase in Eubacteriaceae
was observed. Rifaximin resulted in a significant reduction in network connectivity and clustering on the correlation
networks. The networks centered on Enterobacteriaceae, Porphyromonadaceae and Bacteroidaceae indicated a shift from
pathogenic to beneficial metabolite linkages and better cognition while those centered on autochthonous taxa remained
similar.
Conclusions: Rifaximin is associated with improved cognitive function and endotoxemia in MHE, which is accompanied by
alteration of gut bacterial linkages with metabolites without significant change in microbial abundance.
Trial Registration: ClinicalTrials.gov NCT01069133
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Introduction
Dysfunction of the gut-liver-brain axis in cirrhosis can manifest
as hepatic encephalopathy, the subclinical form of which is
minimal hepatic encephalopathy (MHE) [1]. MHE affects several
cognitive domains that can adversely impact patients in their daily
function [2,3]. The treatment of MHE using gut-selective
strategies can improve cognitive function and quality of life in
patients; however the precise mechanisms of their action are not
clear [4–6]. Rifaximin is a gut-selective antibiotic that has efficacy
in the therapy of HE, traveler’s diarrhea and irritable bowel
syndrome [7,8]. The mechanism of action of rifaximin is
presumed to modulate the concentration of gut microbiota, which
has only been investigated in cirrhosis using culture-based
techniques. However the effect of rifaximin on gut flora using
culture-independent techniques and its effect on gut-derived
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metabolites in the improvement of MHE has not been investigat-
ed.
With the advent of the Human Microbiome project, there has
been substantial focus on characterization of the microbial taxa in
the human gut in disease states [9]. It is now apparent that the gut
microbiome is highly individualized and is influenced by diet and
environmental factors [10]. The resulting taxa abundance data is
non-parametric and sparse, that is there are many taxa that are
present in one individual that are not present in another. From an
ecological perspective, one can hypothesize that this observation
could be explained by the proposition that different taxa perform
the same function in the gut ecosystem [11]. Thus, there are many
discrepancies and confounding observation seen in the current
microbiome literature that tries to correlate microbial taxa with
clinical conditions such as obesity and inflammatory bowel disease
[12,13]. We propose that one needs to take a systems biology
approach to correlate the complex functional dynamic in the gut
ecosystem as a modulator of the gut-brain axis in the human host
[14].
Thus, the aim of this study was to use a systems biology
approach to evaluate the effect of rifaximin therapy on the
metabiome which we define as the interaction between the
phenome (cognition, liver disease severity and endotoxin),
microbiome (stool microbial community) and metabolome (serum
and urine metabolites) in patients with cirrhosis and MHE [15].
The a priori hypothesis was that rifaximin therapy would improve
cognition, reduce endotoxemia, dysbiosis and gut-derived systemic
products in patients with MHE.
Methods
Overall Trial Design
This trial was conducted at the Hunter Holmes McGuire VA
Medical Center between April 2010 through March 2012. Patients
for this trial were recruited after obtaining written informed
consent and underwent all study procedures (Figure 1). The
protocol and checklist for this trial are available as supporting
information; see SI Protocol and Checklist. We screened 31
patients for this study; five were previously on lactulose/rifaximin
and six did not have MHE based on their cognitive performance.
We included twenty patients with cirrhosis who had been
diagnosed with MHE using our pre-defined criteria [two of the
following abnormal compared to our healthy controls, number
connection test A/B (NCT-A/B), Digit symbol (DST) and Block
Design (BDT)] at least 2 months prior to the start of this trial [1] as
has been used and recommended in cirrhosis [16]. We only
included patients with cirrhosis between 18–65 years of age,
without a prior TIPS placement, without prior overt HE and on
treatment for it and those who are able to give written informed
consent. Patients were diagnosed with cirrhosis if they had biopsy
evidence, radiological evidence or endoscopic evidence of varices).
We excluded patients with prior overt HE, who had a recent mini-
mental status exam result of,25, those who scored better than the
inclusion criteria on the cognitive tests and those with prior TIPS
or overt HE. For the first visit, we gave the patients the tests again
to confirm the MHE status and to account for any learning effect.
The patients were prescribed open-label rifaximin 550 mg PO
BID for 8 weeks and the tests were repeated at the end of the
study. Subjects were advised to inform the study staff of any
adverse events and adherence was assessed at week 8 by the
percentage of pills returned.
This report is the microbiome, metabolome and cognitive
analysis of this open-label trial that also involved MR imaging of
the brain before and after rifaximin. It is registered at www.
clinicaltrials.gov number NCT01069133. This trial was conducted
under IND number 7,783 granted to Jasmohan Bajaj by the FDA.
Cognitive Test Battery
We used the following tests at baseline and at the 8 week visit;
BDT and the psychometric hepatic encephalopathy score [PHES;
consists of NCT-A, NCT-B, DST, line tracing test (LTT; has 2
outcomes; errors and time) and serial dotting (SDT)] which have
been validated for use in MHE [17]. Patients also underwent
blood draw for MELD score components (serum bilirubin, serum
creatinine and INR), serum sodium and venous ammonia at
baseline and week 8. A portion of the blood during both visits was
centrifuged to produce serum that was stored at280 degrees C for
metabolomic analysis. We also collected 10 ml of urine during
both visits that was also stored at 280 degrees C for metabolomic
analysis.
Microbiome Analysis
Fresh stool was collected and DNA extracted for microbiome
analysis within 24 h of collection from patients and controls using
published techniques. Microbial community fingerprinting and
multi-tagged pyrosequencing were performed per published
techniques (Text S1) [15]. Metabolomic analysis: Samples were
analyzed using GC and LC mass spectroscopy using published
techniques (details in Text S1, Methods section) [18].
Statistical Analysis
Based on our prior microbiome studies [11] we were able to find
differences in microbiota constituents between advanced cirrhosis
groups with at least 7 subjects in them; we anticipated using 20
patients would be adequate to detect any variation in microbiome
in this relatively compensated population. We compared the
cognitive performance, MELD score (and its individual compo-
nents), venous ammonia and endotoxin levels before and after
rifaximin using paired t-tests. Clinical and microbiome features of
patients before and after rifaximin were compared with a principal
coordinate analysis was also used to show differences between the
two groups. Only taxa with average abundances .1%, P values
,0.05, and low q values (i.e., low risk of false discovery) were
considered significant. Microbiome abundance comparisons be-
tween groups were made at a family level using nonparametric
tests. A comparison was performed between patients before and
after rifaximin using the Wilcoxon matched-pair signed rank tests.
All values are presented as means 6 SD unless mentioned
otherwise.
Metabolomic statistical analyses were performed on all contin-
uous variables using the Statistica DataMiner software version 7.1.
Univariate statistical analysis for multiple study design classes was
performed by breakdown and one-way ANOVA. F statistics and p-
values were generated for all metabolites. Data distributions were
displayed by box–whisker plots, giving the arithmetic mean value
for each category and the standard error as box and whiskers for
1.96 times the category standard deviation to indicate the 95%
confidence intervals, assuming normal distributions. Multivariate
statistical analysis was performed by unsupervised principal
component analysis (PCA) to obtain a general overview of the
variance of metabolic phenotypes in the study [19]. In addition,
supervised partial least-square (PLS) statistical analysis was
performed to obtain information about the variance of metabolic
phenotypes that corresponded to the study design classes [20].
Three plots were obtained for each PCA and PLS model. The first
was a scree plot for the Eigen values of the correlation or
covariance matrix, used as a simple quality check to ensure a steep
descent with an increasing number of Eigen values. Second, 2D
Metabiome and Rifaximin in Cirrhosis
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score scatter plots were generated for at least the first three
dimensionless principal components or PLS vectors, and 3D plots
were generated to better distinguish metabolic phenotypes if
needed. Third, loading plots were generated for each vector in
PCA or PLS, showing the impact of variables on the formation of
vectors.
The abundances of the bacterial identifications were normalized
and taxa present at .1% of the community were tabulated.
Unifrac analysis was performed using Version 1.3.0 of Quantita-
tive Insights into Microbial Ecology (QIIME) and weighted P-
values were calculated using a Bonferroni correction. Correlation
networks were performed separately for groups before and after
rifaximin. The microbiome features along with endotoxin,
ammonia, and metabolomics were correlated using a Spearman’s
correlation function and then filtered for correlations .0.60 and
p,0.05. These correlates were calculated using a custom R
module, and the correlations and corresponding attributes were
imported into Cytoscape for visualization of the network models
[21]. The Intersection of the networks was done using the
advanced network merge function in Cytoscape. A Correlation
Difference (CorrDiff) network was calculated using a R module
which extracts edges whose correlations are statistically different
between the before and after treatment with a P value ,0.05 and
where at least one of the original correlations was greater than
0.06 [22,23]. We then compared the network topology of the
network before and after rifaximin to identify which sub-networks
were present in one and not the other, giving us clues on system
functionality [24]. It is assumed that correlations present in one
treatment group that are missing in another not only differentiate
the groups but indicate potential clues to the functionality of the
system, leading the way to hypothesis-driven experimental
research.
Results
Rifaximin Trial
All patients were able to complete the trial with rifaximin
550 mg BID for 8 weeks. The overall compliance with the
medication was 92%. We included 20 patients, 14 men and 6
women with a mean age of 59.763.5 years and education of
1461.7 years. The majority was Caucasian (14, 70%) with the
remainder being African American (6, 30%). The predominant
etiology was hepatitis C (7, 35%), followed by alcohol+hepatitis C
(4, 20%), non-alcoholic fatty liver disease (4, 20%), alcohol alone
Figure 1. Consort Flowchart of the Open-label trial.
doi:10.1371/journal.pone.0060042.g001
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(3, 15%) and others (2, 10%). There was a significant improvement
in serum bilirubin but not the other MELD score components at
the end of the trial (Table 1). There was also a significant
improvement in cognitive performance on all tests apart from the
block design test compared to the pre-treatment baseline. There
was a significant reduction in endotoxin levels after rifaximin
therapy compared to baseline (0.5560.21 vs. 0.4860.24 Eu/ml,
p = 0.02).
Microbiome Changes
There was no significant difference in the overall microbiome
composition before and after rifaximin upon visual inspection of
the principal component analysis (Figure 2A). UNIFRAC PCO
analysis also did not show a significant clustering between the
microbiota composition before and after rifaximin (Figure S1).
However, the UNIFRAC Bonferroni corrected, weighted signif-
icance test for the treatments was indicated a slight difference
between the microbiome compositions (p = 0.01) There was a
significant reduction in the abundance of the taxa Veillonellaceae
(p = 0.025) and increase in the abundance of Eubacteriaceae
(p = 0.042) using Metastats but no other significant changes in
the microbiome abundance were observed after rifaximin therapy
(Figures 2B and 2C).
Metabolome Analysis
There was a significant difference in serum and urine
metabolites between groups before and after rifaximin using
Partial Least Squares Discriminant Analysis (PLS-DA) (figures
S2A and B). Uni-variate analysis of serum metabolites (Figure 3)
showed that the majority of the differentiators were serum fatty
acids that increased after rifaximin therapy. The pattern of fatty
acid increase after rifaximin were a higher level of saturated fatty
acids [caprylic (8:0), myristic (14:0) and palimitic acid (16:0)] which
after the action of stearoyl-CoA desaturase can be turned into
palmitoleic acid (16:1n7), oleic (18:1n9) and eicosanoic acid
(20:1n9). An increase in linolenic acid (18:3n3), gamma-linolenic
acid, linoleic (18:2n6) and arachidonic acid (20:3n6) formed by the
action of delta 6-desaturase and fatty acid elongase was also seen.
There was also an increase in serum fructose, succinic acid and
citramalic acid after rifaximin. The only significant uni-variate
change in urine metabolites was a minor increase in urine succinic
acid.
Correlation Network Analysis
We ran the Spearman correlation network analysis on the 2,238
features in the dataset (Table S1) and selected correlation for both
‘‘Before’’ and ‘‘After’’ treatment that had an absolute Spearman
Correlation Coefficient greater than 0.6 and P-value ,0.05 The
global correlation networks are very complex with 153,000
correlations (2,220 nodes) for the ‘‘before’’ correlation network
(BCN) (Figure 4A) and 57,249 correlations (2,225 nodes) for the
‘‘after’’ correlation network (ACN) (Figure 4B).
We calculated the intersection correlation network (ICN) which
plots all the correlations that are the same in both the BCN and
ACN (Figure 4C). Interestingly, over 99% of the features in the
dataset are found in the intersection correlation network. Thus,
this intersection correlation network delineates the stable core
metabiome of the cirrhotic state that didn’t change during
treatment. Visually, there is a major hub of urine metabolites
with a minor hub of serum metabolites connected by various
minor clusters.
The complexity of the networks is expected as many compounds
will be in the same or complementary metabolic pathway. The
networks are visually different and this is reflected in the
connectivity measurements (Table 2). For example, the average
number of neighbors for the BCN is 59 while it is 51 for the ACN.
These parameters indicate that rifaximin has a major effect of the
metabolic network, reducing a number of the metabolic interac-
tions and reducing the clustering, while keeping the nodes
themselves intact.
When we plotted the Cumulative Distribution Function (CDF)
of the node degree frequency(14), we found that the connectivity
simplified after rifaximin (Figure 4D) and this was a statistically
significant shift (P,0.001). We found that most of the nodes
included in the BCN and ACN are contained in the ICN [2219
nodes] but it contains a much smaller subset of the correlations
with an average number of neighbors of 13.5. Thus, despite most
of the features being present before and after rifaximin therapy,
the connectivity changed significantly after rifaximin. This is in
contrast to a much more minimal effect on the bacterial
abundances of the microbiome. This implies that rifaximin, which
is a bacterial RNA polymerase inhibitor, does not seem to alter the
relative bacterial abundances but does promote a major shift in the
complexity of the peripheral metabiome network implying a shift
in the gut microbiome functionality.
We then calculated the Correlation Difference network
(CorrDiff) (Figure 4E) which is a global view of which correlations
changed significantly after treatment with rifaximin. We selected
only correlation differences that had a Pvalue ,0.05 and where at
least one of the original Spearman correlation was greater than
0.6. This network contains only 1490 features, which is
substantially smaller than the original BCN with only 67% of
the original features. Visual inspection of the CorrDiff (Figure 4E)
shows a more complex network of hubs that is reflected in the
Network Heterogeneity (2.012) and Clustering Coefficient (0.79).
Additionally, one can see that a number of correlations
involving bacteria (red squares) were changed by the rifaximin
treatment Figure 4D). We found five bacterial taxa (Enterobacteri-
aceae, Bacteroidaceae, Veillonellaceae, Porphyromonadaceae and Rikenella-
ceae) that showed a significant difference in correlations before
rifaximin compared to after rifaximin using the correlation
difference network. Subnets centered on these taxa from the
global BCN and ACN were then visualized (figures S3–S7 in File
Table 1. Changes in cognition and cirrhosis severity with
rifaximin therapy.
N=20 Baseline After rifaximin
MELD score 9.863.3 9.463.1
INR 1.260.2 1.260.2
Serum creatinine (mg/dl) 0.960.1 0.960.2
Serum bilirubin (mg/dl) 1.360.8 1.160.7*
Serum sodium (meq/L) 138.162.8 138.962.7
Venous ammonia 46.2623.4 42.9623.1
Cognitive tests
Number connection-A (seconds) 42.3613.4 37.368.9*
Number connection-B (seconds) 97.2631.9 85.7625.8*
Digit symbol (raw score) 50.0612.3 55.1613.9*
Block design (raw score) 25.9611.9 28.569.6
Line tracing time (seconds) 121.7632.1 96.4633.1*
Line tracing errors (number) 41.2628.3 24.8617.1*
Serial dotting (seconds) 69.6625.7 61.0617.3*
doi:10.1371/journal.pone.0060042.t001
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S1, Text S1). To aid in interpretation, the nodes that were
‘‘unassigned’’ or not yet identified were removed from correlation
networks unless they served as a bridge between two named
features in the subnets.
Correlation Differences before and after Rifaximin
Therapy
To identify relationships that changed significantly between
baseline and post-rifaximin, we specifically analyzed data on
microbiome, significantly different serum metabolites, and clini-
cal/cognitive data (Figure 5). We found that Bacteroidaceae changed
their linkages from being positively correlated with NCT-B
(indicates poor cognition) and glycocholic acid before to a negative
correlation after; also there was a reduction in intensity of the
positive correlation with glutamic acid and asparagine, both
ammonia sources after rifaximin. Glutamic acid changed from
negative to positive with Lachnospiraceae. We also found that in the
network, serum fatty acids (linoleic, linolenic and oleic, and
isolinoleic, lauric, myristic and palmitoleic acids) remained
correlated with each other positively while the arachidonic acid
was initially positively but then negatively linked to ammonia after
rifaximin. A high score on SDT indicates poor cognition so it is
also interesting that stearic acid, changed its linkage from positive
to negative with that cognitive test as well as with autochthonous
taxa Lachnospiraceae and Incertae Sedis XIV. These correlation
differences are key in evaluating the potential effects of rifaximin
on cognition.
Figure 2. A: Principal Component Analysis of Microbiota. There was no significant change in the PCO of microbiota before and after rifaximin
therapy (yellow dots are before and red dots are after rifaximin) B and C: Composition of microbiota families before (figure 2B) and after (figure 2C)
rifaximin. There was a significant decrease in Veillonellaceae and increase in Eubacteriaceae abundance after rifaximin therapy (marked in red).
doi:10.1371/journal.pone.0060042.g002
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Discussion
This clinical trial demonstrates that rifaximin is associated with
improved cognitive performance and reduction in endotoxemia in
patients with cirrhosis and MHE. This was associated with a
modest change in the stool microbiota characterization with
reduced Veillonellaceae and increased Eubacteriaceae. There was a
significant change in the serum metabolome with a specific
increase in serum fatty acids after rifaximin therapy. Correlation
networks showed that key bacterial families, Porphyromonadaceae,
Bacteroidaceae and Enterobacteriaceae had differing associations with
the metabolome and microbiome after rifaximin compared to
baseline linkages.
The use of rifaximin for MHE therapy is an attractive
proposition due to its efficacy, tolerability and gut-specific action
[4,5,7]. In vitro the rifaximin is able to act on a wide variety of
gram-positive and negative organisms [8]. However there is
emerging evidence that its primary mode of action may be related
to a change in bacterial function and virulence rather than a
simple reduction in bacterial population. Studies in Escherichia coli
and Shigella sonnei, virulent members of Enterobacteriaceae have shown
that rifaximin exposure results in a reduction in its virulence and
ability to adhere to intestinal cells while keeping the counts
comparable to baseline [25,26]. Also fecal microbiota studies from
Crohn’s disease patients have shown that there was a change in
bacterial end-products such as short-chain fatty acids and alcohols,
after rifaximin therapy, rather than an absolute difference in
numbers [27].
Confirming and extending these investigations into cirrhosis and
MHE, we did not find an overall significant change in microbiota
composition at the phylum or order level but there was a modest
reduction in Veillonellaceae and a trend towards increased Eubacter-
iaceae. Veillonellaceae are anerobic gram-negative cocci that have
been found to be higher in abundance in cirrhotic patients’ stool
and colonic mucosa compared to healthy controls [28]. Also, prior
studies show that their abundance is greater in the colonic mucosa
of cirrhotics with HE compared to those without HE and lesser in
those on rifaximin and lactulose compared to lactulose alone [29].
Veillonella spp have also been over-represented in patients with
irritable bowel syndrome, most often those with a mixed or
constipation-predominant clinical picture [30]. The presence of
Veillonellaceae may be a marker for the presence of HE and MHE in
the stool and colonic mucosa of cirrhotic patients [11,29]. Since
the major fermentative substrate for Veillonella is lactic acid, it often
has a symbiotic relationship with taxa such as Streptococcaceae whose
end-product of metabolism is lactate. There was a trend towards
reduction in Streptococcaceae with rifaximin which could also factor
into the reduction of Veillonellaceae in this population. Comple-
mentary to our findings, Eubacteriaceae often respond in directions
opposite to that of Veillonellaceae after dietary manipulation [31].
There was also a change in the overall network connectivity
before and after rifaximin. This is interesting because it shows that
although the network features, i.e. microbiota and metabolome are
present in the networks before and after rifaximin, rifaximin
therapy decentralized and reduced clustering and decreased the
overall complexity of the connections between the same nodes.
This supports a change in bacterial metabolic function rather than
a change in bacterial numbers as the probable cause of its action.
When we specifically studied families that have been associated
with cirrhosis in the network, a significant change in connectivity
before and after rifaximin was observed with respect to
metabolites. Prominent among them were changes in Bacteroidaceae,
Enterobacteriaceae, and Porphyromonadaceae. All three taxa have been
associated with cirrhosis, HE and cognitive dysfunction in the past
and include several pathogenic genera such as Escherichia, Shigella,
Alistipes, Porphyromonas, Bacteroides and Salmonella [11,28,32]. At
baseline, these taxa were correlated with products of aromatic
amino acid and ammonia metabolism and oxidative stress
indicators [28,33]. These correlations changed to become
beneficial, i.e. negatively correlated with oxidative stress or with
aromatic amino acid and nitrogen metabolism after rifaximin.
Interestingly, there was also evidence of several quorum sensors in
the correlation network that can influence the number of co-
existent microbiota, especially those belonging to Enterobacteriaceae
[34]. We also were able to confirm that the autochthonous taxa
continued to be beneficially linked to metabolites before and after
rifaximin therapy [29]. While correlations do not imply causality,
as a whole the network analysis indicates that the associations
between metabolites and microbiota changed after rifaximin
Figure 3. Univariate serummetabolomic analysis. There was a significant increase in fatty acids and intermediates of carbohydrate metabolism
after rifaximin therapy in the serum.
doi:10.1371/journal.pone.0060042.g003
Metabiome and Rifaximin in Cirrhosis
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Figure 4. Correlation networks before and after rifaximin. Legend common for figures 4A, 4B and 4C: The complex correlation network
represented parameters that were linked with a correlation coefficient .0.6 (negative or positive) and with a p value ,0.05. Red nodes represent
bacterial taxa, green ones the serum metabolites, yellow nodes indicate urinary metabolites while blue ones indicate clinical parameters. Red edges
Metabiome and Rifaximin in Cirrhosis
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therapy into a potentially beneficial metabiomic milieu for the
host.
Lipopolysaccharide (endotoxin) was significantly reduced in
patients taking rifaximin, in the current study consistent with
previously reported studies of HE and cirrhosis patients [35].
Moreover, there was a significant increase in serum long-chain
fatty acids in patients on rifaximin as compared to controls. The
absorption of endotoxin and long-chain fatty acids are believe to
primarily occur in the small bowel as bile salts are important for
the solubilization of hydrophobic compounds. Both endotoxin and
long-chain fatty acid are transported packaged in chylomicrons
which are formed in enterocytes in the small bowel [36].
Therefore, we hypothesize that main effect of rifaximin may be
to inhibit bacterial growth and reduce endotoxin absorption in the
small bowel. This is consistent with the reduction of members of
the family Veillonellaceae, which are Gram-negative anaerobic cocci
and have been reported to be in relatively high numbers in the
human ileum [37].
After rifaximin therapy, there was an increase in long-chain
saturated fatty acids along with products of stearoyl CoA
desaturase. We also found a significant increase in unsaturated
fatty acids with higher linoleic, conjugated linoleic, linolenic and
arachidonic acids after the treatment with rifaximin. This specific
fatty acid profile is interesting because animal studies have shown
that it is possible to modify the adipose tissue and peripheral fatty
acid profile with introduction of probiotics or bacteria that have
specific fatty acid enzyme mutations [38]. Also these studies found
that these changes in peripheral fatty acid changes can benefit
brain fatty acid constitution in these animals giving a potential
mechanism for the biological effect of gut bacteria on brain
function [39]. This increase is unlikely to be dietary since the diet
remained constant throughout the study and there was no change
in the mead acid level, which is a marker for dietary intake change
between the pre and post-rifaximin profile [40]. Therefore the
increased fatty acids are likely either due to an enhanced transport
from the gut to the bloodstream via the thoracic duct as
chylomicrons or enhanced release from the adipose tissue. Gut
microbiota can affect adipose tissue and peripheral lipoprotein
lipase by modulating the fasting-induced adipose factor [41,42].
The lack of short-chain fatty acids, which are major end-products
of bacterial fermentation, in this serum profile is likely because the
majority of their biological activity occurs within the gut lumen
and they are directly absorbed and transported into the liver [43].
The predominance of long-chain serum fatty acids in the post-
rifaximin profile supports the gut-based transport of these
molecules in chylomicrons as a potential mechanism for their
higher levels. Prior studies have shown that fatty acids, both
saturated and unsaturated, are associated with brain function in
animal, human and population-based studies[39,44–46]. The
brain fatty acid profile impacts neurogenesis, cognition and
memory possibly by affecting neurotransmission, axonal sheath
composition and cell membrane fluidity. Fatty acids increased in
our study, arachidonic and linoleic acids, have been shown to
influence brain function directly [44,46]. There was a significant
represent negative correlation between connected nodes and blue edges indicate positive correlations. A: Correlation network before rifaximin (BCN)
with r.0.6 or ,20.6 and p,0.001. B: Correlation network after rifaximin (ACN) with r.0.6 or ,20.6 and p,0.001. C: is the intersection of 5A and B.
It demonstrates those nodes and correlations that remain exactly same before and after rifaximin. D: Cumulative Degree Function curve. This graph
plots the cumulative degree function of the node frequency distributions before and after rifaximin. It shows that after rifaximin therapy there was a
significant reduction in network complexity (p,0.0001). Blue line: before and red line: after rifaximin. E: Correlation difference before and after
rifaximin. This figure shows the correlations that significantly changed between the before and after rifaximin state; i.e. if two nodes were connected
positively in the before rifaximin network but aftr rifaximin changed to negative, they are represented here. While the color coding of the nodes is
similar, red edges demonstrate linkages that were positive in the BCN but became negative in ACN, while blue edges represent correlations that
changed from negative to positive after the use of rifaximin.
doi:10.1371/journal.pone.0060042.g004
Table 2. Comparison of network topology before and after rifaximin.
Before Rifaximin After Rifaximin
Intersection of the two
networks
Number of Nodes 2220 2225 2219
Isolated Nodes 0 0 511
Connected Components 1 1 547
Average Number of Neighbors 59.0405405 51.4588764 13.5205047
Network Density 0.02660682 0.02313798 0.00609581
Clustering Coefficient (saturation of the nodes) 0.36257932 0.33746817 0.31452636
Network Diameter (largest distance between nodes) 6 6 15
Network Radius (shortest distance between nodes) 4 4 1
Characteristic Path Length (expected distance between two
nodes)
2.77271111 2.75946771 4.68771603
Network Centralization 0.23453281 0.18386182 0.15184087
Shortest Path (shortest path through all nodes) 4926180 4948400 2600364
Network Heterogeneity (tendency to form hubs) 1.19030892 1.05451615 1.80374813
Intersection indicates the nodes and network common to both before and after rifaximin. The table shows that the majority of nodes involved were common
(intersection) between the groups while the network density (average number of neighbors and network density) changed after rifaximin therapy. While the diameter
and radius remained same, there was a reduction in the path length and heterogeneity after rifaximin compared to before. There was also a decrease in network
centralization which means that the distribution was spread out after rifaximin therapy compared to before.
doi:10.1371/journal.pone.0060042.t002
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improvement in their cognitive function after rifaximin therapy
across most cognitive domains. While our study did not evaluate
mechanisms, it can be speculated that changing the gut bacterial
end-product and fatty acid profile could benefit this cognitive
ability by potentially affecting the brain fatty acid profile.
We observed that rifaximin does not alter the relative bacterial
abundances but does promote a major shift in the complexity of
the metabiome network. However, we did not measure absolute
abundances of the taxa in the microbiome. Thus, there is a
possibility that rifaximin may have had an impact on total
microbial mass in the gut that may also play a role in the
modulation of the metabiome to improve MHE.
A limitation of this study was that the majority of the
metabolome features were unidentified due to limitations in the
GC and LC MS databases. Future studies should focus on
delineating those metabolites that are at key nodes in the major
network hubs of the CorrDiff or are key links between metabiome
components. The fecal metabolome and small bowel microbiota
analysis could have given additional insight into the mechanism of
action of rifaximin. Our sample size was also limited, which could
have potentially impeded our ability to characterize changes in
microbial abundance, since there is considerable inter-individual
microbial variability. Also our study is limited by the evaluation of
fecal bacteria, which could have differing abundances from that of
the colonic and small bowel mucosal bacteria [29]. However,
given these limitations, we were still able to detect changes that are
physiologically plausible and relevant to the ultimate result which
is improvement in cognition and reduction in endotoxemia after
rifaximin therapy.
We have demonstrated that a systems biology approach using
network correlation analysis and correlation difference analysis
was much more informative in interpreting the interaction of the
metabiome (i.e. phenome, microbiome and metabolome) than
current multivariate analyses. We postulate that the metabiome is
a complex non-linear dynamic and interrogating this dynamic
with one time point cannot completely capture the fluctuation in
the metabolic network. Additionally, microbiome identification
alone may have limited utility in that many taxa may have the
same metabolic function in the gut ecosystem. Thus, methodology
interrogating functional aspects of the metabiome, such as the
metabolome and metatranscriptome, should prove more informa-
tive.
We conclude that rifaximin therapy has a systemic and local
effect on the microbiota, metabolome, endotoxemia and cognition
in patients with minimal hepatic encephalopathy. A significant
improvement in cognition with reduction in endotoxemia was
observed with a modest change in stool microbiota composition.
There was a significant increase in serum long-chain fatty acids
after rifaximin therapy. We also found a significant linkage of
bacterial taxa with the metabolites, especially those linked to
ammonia, aromatic amino acids and oxidative stress, which shifted
to reflect changes in bacterial metabolic function after rifaximin
therapy. Therefore the mechanism of action of rifaximin, based on
our results, may be associated with changing microbiota-associated
metabolic function leading to cognitive improvement.
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Figure 5. Subset of correlation differences before and after rifaximin. This figure is limited to the metabolomics and clinical/cognitive
features that changed with rifaximin and their interaction with the bacterial taxa. The linkages that significantly changed in nature (positive to
negative or vice-versa) or intensity (less to more or vice-versa while remaining positive or negative) with p,0.05 are shown. Nodes: Blue: bacterial
taxa, green: serum metabolites, Yellow: cognitive or clinical data. Linkages were dark blue if correlations were positive before and changed
significantly to negative, light blue if they changed significantly but remained positive throughout, red if correlations were negative at baseline but
changed to positive after therapy and green is negative relationship throughout but a significant change.
doi:10.1371/journal.pone.0060042.g005
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